Chris Brickley
Senior Manager of IR & Corporate Communication

Good morning, everyone. I'm Chris Brickley, Director of Investor Relations at Alnylam, and I'm pleased to be kicking off our 10th RNAi Roundtable series this morning. Throughout these events, we aim to highlight a few of the exciting programs in our pipeline that represent some of the next wave of transformative medicines we expect to deliver from our RNAi platform.

Today, we'll be covering ALN-6400, which is an investigational therapy targeting plasminogen with the potential to address rare bleeding disorders. Today's event is expected to run approximately 75 minutes. Pushkal will moderate a question-and-answer session at the conclusion of the presentations. And if you'd like to submit a question, you can do so at any time during the event by typing your question in the Ask a Question field located within the webcast platform.

As a reminder, we will be making forward-looking statements during this webinar, and we encourage you to read our most recent SEC filings for a more complete discussion of our risk factors. With that, I'd like to turn it over to Pushkal Garg, our Chief Research and Development Officer. Pushkal?

Pushkal Garg
Executive VP & Chief Research & Development Officer

Thanks, Chris, and welcome, everyone, to today's roundtable on ALN-6400, which we believe represents a potentially transformative RNAi therapeutic for patients living with rare bleeding disorders. With me today are 2 accomplished scientists, who embody our world-class R&D capabilities, John Gansner, Hematologist and Executive Director and the Program Lead for the ALN-6400 Program; and Martina Slingsby, Senior